MAIA Biotechnology, Inc.
AMEX:MAIABiotechnology
+$0.05 today
- Market cap
- $80.28M
- Beta
- 0.24
- P/E (TTM)
- -1.8
- EPS (TTM)
- -$0.76
Volume 2.25M
Average 0.78M
MAIA Stock-Based Compensation
Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.
MAIA Biotechnology, Inc.AMEX: MAIA
Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026
Stock-based compensation growth accelerates
Q1 FY2026 stock-based compensation of $650.02K rose 75.0% year over year, ahead of the +50.5% change in trailing-twelve-month stock-based compensation. Sequentially, it fell 19.8% from the prior quarter. Over 3 fiscal years it compounded at +4.3% a year.
Context
- Stock-based compensation increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth of +75.0% holds above the trailing-twelve-month pace of +50.5%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Stock-Based Compensation history
USD · from the cash flow
- Latest · FY2025
- 2.63M USD
- Year-over-year change
- +37.6%
- 4-year CAGR
- -0.8%
| Period | Period end | Stock-Based Compensation | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 2.63M | +37.6% |
| FY2024 | 2024-12-31 | 1.91M | -38.1% |
| FY2023 | 2023-12-31 | 3.09M | +33.2% |
| FY2022 | 2022-12-31 | 2.32M | -14.8% |
| FY2021 | 2021-12-31 | 2.72M | — |
Stock-Based Compensation vs competitors
How MAIA compares with its peers on the latest reported figures
- MAIA's LTM Mar 2026 stock-based compensation of $2.91M is the 3rd largest of the 7 companies compared; the peer median is $1.39M.
- Its year-over-year change of +50.5% is the highest of 6, against a peer median of -32.6%.
- Over three fiscal years its annual growth of +4.3% compares with a peer median of -10.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Dec 2025 | $10.38M | -11.5% | -13.2% | 39.1% | |
| LTM Mar 2026 | $4.36M | -62.1% | -10.3% | — | |
| LTM Mar 2026 | $2.91M | +50.5% | +4.3% | — | |
| LTM Mar 2026 | $1.48M | -62.7% | +481.3% | — | |
| LTM Mar 2026 | $1.3M | +24.7% | +25.3% | 87.0% | |
| LTM Mar 2026 | $503.13K | -32.6% | -18.2% | — | |
| LTM Dec 2025 | $0 | — | — | — | |
| Peer median (excluding MAIA) | $1.39M | -32.6% | -10.3% | 63.1% | |
Competitors are the stored peer set for MAIA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (12.58M) | (15.77M) | (19.77M) | (23.25M) | (22.4M) |
| Depreciation & Amortization | 0 | 0 | 0 | 0 | 0 |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 2.72M | 2.32M | 3.09M | 1.91M | 2.63M |
| Change in Working Capital | 1.13M | 352.78K | 3.09M | (1.24M) | 1.5M |
| Accounts Receivables | 0 | (269.4K) | 158.41K | 56.81K | 80.41K |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 805.52K | 211.35K | 471.9K | (118.83K) | 519.72K |
| Other Working Capital | 320.23K | 410.83K | 2.46M | (1.18M) | 899.19K |
| Other Non-Cash Items | 4.61M | 1M | 526.53K | 6.88M | (579.4K) |
| Operating Cash Flow | (4.12M) | (12.1M) | (13.07M) | (15.7M) | (18.84M) |
| Capital Expenditures | 0 | 0 | 0 | 0 | 0 |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | 0 | 0 | 0 | 0 | 0 |
| Debt Repayment | 7.43M | 0 | 0 | 0 | 0 |
| Common Stock Issued | 5.74M | 13.97M | 11.42M | 18.75M | 18.52M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 860.43K | (1.5M) | (2.15M) | (578.1K) | (617.13K) |
| Financing Cash Flow | 14.03M | 12.48M | 9.27M | 18.18M | 17.91M |
| Effect of Forex Changes | 0 | (4.43K) | (117) | (21.55K) | (5.22K) |
| Net Change in Cash | 9.91M | 376.64K | (3.8M) | 2.45M | (943.27K) |
| Free Cash Flow | (4.12M) | (12.1M) | (13.07M) | (15.7M) | (18.84M) |
MAIA Biotechnology, Inc.
AMEX:MAIA
Intrinsic Alpha fair value
Locked
Current Price
$1.30
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.